The conference committee for legislation to combat the opioid epidemic met for the first time this week since early April. Despite finally calling a meeting, Senate Republicans planned to take no formal action on the bill. Instead, state agencies provided presentations on existing state and federal funding for opioid addiction, and more time was allotted for public testimony.
The House and Senate have only come to agreement on a handful of noncontroversial provisions in the bill. At the heart of the ongoing disagreement is a section in the Senate bill, opposed by DFLers, to sunset the highest fees charged to the pharmaceutical industry if Minnesota receives more than $20 million from any of the active litigation against drug manufacturers.
DFLers are still hopeful that an agreement can be reached before the end of session, but time is running out. (HF 400)